Pendrik Tandean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pendrik Tandean has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Andi Alfian Zainuddin
Department of Public Health and Community Medicine, Faculty of Medicine, University of Hasanuddin, Makassar, Indonesia
3 shared publications - Syakib Bakri
Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
3 shared publications - Akhyar Albaar
Internal Medicine Makassar South Sulawesi 90245 Hasanuddin University School of Medicine
2 shared publications - Haerani Rasyid
Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
2 shared publications - Hasyim Kasim
Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
2 shared publications - Sitti Rabiul Zatalia Ramadhan
Department of Internal Medicine Makassar South Sulawesi 90245 Hasanuddin University
2 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 34 (2)
Association Between Glycemic Variability Indices and Clinical Outcomes in Patients Without Diabetes Presenting with ST-Segment Elevation Myocardial Infarction: A Prospective Cohort Study
Introduction. Glycemic variability (GV) has emerged as a potential prognostic marker in acute cardiovascular conditions. While its association with adverse outcomes has been widely studied in diabetic populations, limited data exist regarding its clinical impact in non-diabetic patients presenting with ST-segment elevation myocardial infarction (STEMI). Aim. This study aimed to evaluate the association between glycemic variability indices and short-term clinical outcomes in non-diabetic patients with STEMI. Materials and Methods. This prospective cohort study included 133 non-diabetic patients with STEMI admitted to a tertiary cardiac center. Blood glucose levels were measured serially during the first five days of hospitalization. Glycemic variability was assessed using the coefficient of variation (CoV), with a median cut-off value of 13.2 % used to categorize patients into low and high GV groups. Clinical outcomes, including mortality, heart failure, recurrent angina, and stroke, were assessed during hospitalization and up to 30 days to three months after discharge. Statistical analysis was performed using bivariate tests, with p<0.05 considered statistically significant. Results. The median age of participants was 60 years, and 78.2 % were male. Mortality occurred in 13.5 % of patients, heart failure in 74.4 %, recurrent angina in 30.1 %, and stroke in 8.3 %. No statistically significant associations were found between high GV (CoV≥13.2 %) and mortality (p=0.327), heart failure (p=0.959), recurrent angina (p=0.955), or stroke (p=0.110). Conclusions. In non-diabetic patients with STEMI, glycemic variability assessed during the acute hospitalization period was not significantly associated with short-term adverse clinical outcomes. These findings suggest that moderate glucose fluctuations in this population may not independently predict early complications.
- 29 June 2026
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 34 (2)
Open AccessAssociation Between Glycemic Variability Indices and Clinical Outcomes in Patients Without Diabetes Presenting with ST-Segment Elevation Myocardial Infarction: A Prospective Cohort Study
Introduction. Glycemic variability (GV) has emerged as a potential prognostic marker in acute cardiovascular conditions. While its association with adverse outcomes has been widely studied in diabetic populations, limited data exist regarding its clinical impact in non-diabetic patients presenting with ST-segment elevation myocardial infarction (STEMI). Aim. This study aimed to evaluate the association between glycemic variability indices and short-term clinical outcomes in non-diabetic patients with STEMI. Materials and Methods. This prospective cohort study included 133 non-diabetic patients with STEMI admitted to a tertiary cardiac center. Blood glucose levels were measured serially during the first five days of hospitalization. Glycemic variability was assessed using the coefficient of variation (CoV), with a median cut-off value of 13.2 % used to categorize patients into low and high GV groups. Clinical outcomes, including mortality, heart failure, recurrent angina, and stroke, were assessed during hospitalization and up to 30 days to three months after discharge. Statistical analysis was performed using bivariate tests, with p<0.05 considered statistically significant. Results. The median age of participants was 60 years, and 78.2 % were male. Mortality occurred in 13.5 % of patients, heart failure in 74.4 %, recurrent angina in 30.1 %, and stroke in 8.3 %. No statistically significant associations were found between high GV (CoV≥13.2 %) and mortality (p=0.327), heart failure (p=0.959), recurrent angina (p=0.955), or stroke (p=0.110). Conclusions. In non-diabetic patients with STEMI, glycemic variability assessed during the acute hospitalization period was not significantly associated with short-term adverse clinical outcomes. These findings suggest that moderate glucose fluctuations in this population may not independently predict early complications.
- Open Access
- 25 December 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (4) , 147-155
Effect of Macrolide and Non-Macrolide Therapy on QTc Interval Prolongation in Cardiac Patients with Community-Acquired Pneumonia
Introduction. Azithromycin is a macrolide antibiotic widely used to treat various infectious diseases, such as respiratory infections. Several studies have reported an association between azithromycin and QT interval prolongation. QTc prolongation is one of the causes of the life-threatening arrhythmia torsade de pointes (TdP). Torsade de pointes has been reported in approximately 1 % of patients with QT interval prolongation after exposure to azithromycin. Aim. This study aims to determine the effect of macrolide and non-macrolide regimen therapy on the prolongation of the QTc interval in cardiac patients with community-acquired pneumonia. Materials and Methods. This is a retrospective cohort study of 33 cardiac patients with community-acquired pneumonia who received macrolide and non-macrolide therapy during hospitalization. Serial electrocardiograms were performed on days 1, 3, 5, and pre-discharge to evaluate the QTc interval. Outcomes. In the group of heart disease patients with community-acquired pneumonia who received macrolides, there was a significant prolongation of the QTc interval (p<0.05) in the independent T-test, Mann-Whitney test, and Friedman test. Risk factors of age, female gender, history of hypertension, and diabetes mellitus had a significant effect (p<0.05) in the Friedman test. Conclusions. This study shows that macrolide therapy in heart disease patients with community-acquired pneumonia significantly and consistently prolongs the QTc interval throughout the treatment period compared with non-macrolide therapy. Risk factors include age, female gender, history of hypertension, and diabetes mellitus.
- 25 December 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (4) , 147-155
Open AccessEffect of Macrolide and Non-Macrolide Therapy on QTc Interval Prolongation in Cardiac Patients with Community-Acquired Pneumonia
Introduction. Azithromycin is a macrolide antibiotic widely used to treat various infectious diseases, such as respiratory infections. Several studies have reported an association between azithromycin and QT interval prolongation. QTc prolongation is one of the causes of the life-threatening arrhythmia torsade de pointes (TdP). Torsade de pointes has been reported in approximately 1 % of patients with QT interval prolongation after exposure to azithromycin. Aim. This study aims to determine the effect of macrolide and non-macrolide regimen therapy on the prolongation of the QTc interval in cardiac patients with community-acquired pneumonia. Materials and Methods. This is a retrospective cohort study of 33 cardiac patients with community-acquired pneumonia who received macrolide and non-macrolide therapy during hospitalization. Serial electrocardiograms were performed on days 1, 3, 5, and pre-discharge to evaluate the QTc interval. Outcomes. In the group of heart disease patients with community-acquired pneumonia who received macrolides, there was a significant prolongation of the QTc interval (p<0.05) in the independent T-test, Mann-Whitney test, and Friedman test. Risk factors of age, female gender, history of hypertension, and diabetes mellitus had a significant effect (p<0.05) in the Friedman test. Conclusions. This study shows that macrolide therapy in heart disease patients with community-acquired pneumonia significantly and consistently prolongs the QTc interval throughout the treatment period compared with non-macrolide therapy. Risk factors include age, female gender, history of hypertension, and diabetes mellitus.
- Open Access
- 25 June 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (2) , 75-80
Ejection Fraction Decline and Cardiotoxicity Following Anthracycline Chemotherapy: A Risk-Focused Study from an Indonesian Tertiary Care Center
Background. Anthracycline chemotherapy is a cornerstone of cancer treatment but poses a risk of cardiotoxicity, often presenting as cancer therapy–related cardiac dysfunction (CTRCD). Monitoring left ventricular ejection fraction (LVEF) is essential to detect early cardiac impairment and support safer treatment strategies. Aim. To assess LVEF changes after six cycles of anthracycline therapy and identify predictive factors associated with CTRCD. Materials and methods. This observational pre–post study included 74 patients treated with anthracyclines at Dr. Wahidin Sudirohusodo Hospital, Makassar, from 2024 to 2025. LVEF was measured via echocardiographic surveillance before and after treatment. Cardiotoxicity was defined as a ≥10 % decrease in LVEF to ≤50 %. Statistical tools included Wilcoxon signed-rank test, Chi-square, ROC curve analysis, and logistic regression. Results. The mean LVEF significantly declined from 63.08 % to 56.76 % (p = 0.001). CTRCD occurred in 20.3 % of patients. Risk factors independently associated with cardiotoxicity included age ≥51 years (OR 2.80; p = 0.016) and cumulative anthracycline dose ≥457.5 mg/m² (OR 3.25; p = 0.004). When both factors were present, the risk increased nearly sixfold (OR 5.75; p = 0.001). Conclusions. CTRCD was observed in one-fifth of patients following anthracycline therapy, with age and dose being significant contributors. These findings support the integration of risk-based echocardiographic surveillance into oncology care to ensure early detection and mitigate long-term cardiac complications.
- 25 June 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (2) , 75-80
Open AccessEjection Fraction Decline and Cardiotoxicity Following Anthracycline Chemotherapy: A Risk-Focused Study from an Indonesian Tertiary Care Center
Background. Anthracycline chemotherapy is a cornerstone of cancer treatment but poses a risk of cardiotoxicity, often presenting as cancer therapy–related cardiac dysfunction (CTRCD). Monitoring left ventricular ejection fraction (LVEF) is essential to detect early cardiac impairment and support safer treatment strategies. Aim. To assess LVEF changes after six cycles of anthracycline therapy and identify predictive factors associated with CTRCD. Materials and methods. This observational pre–post study included 74 patients treated with anthracyclines at Dr. Wahidin Sudirohusodo Hospital, Makassar, from 2024 to 2025. LVEF was measured via echocardiographic surveillance before and after treatment. Cardiotoxicity was defined as a ≥10 % decrease in LVEF to ≤50 %. Statistical tools included Wilcoxon signed-rank test, Chi-square, ROC curve analysis, and logistic regression. Results. The mean LVEF significantly declined from 63.08 % to 56.76 % (p = 0.001). CTRCD occurred in 20.3 % of patients. Risk factors independently associated with cardiotoxicity included age ≥51 years (OR 2.80; p = 0.016) and cumulative anthracycline dose ≥457.5 mg/m² (OR 3.25; p = 0.004). When both factors were present, the risk increased nearly sixfold (OR 5.75; p = 0.001). Conclusions. CTRCD was observed in one-fifth of patients following anthracycline therapy, with age and dose being significant contributors. These findings support the integration of risk-based echocardiographic surveillance into oncology care to ensure early detection and mitigate long-term cardiac complications.
- Open Access
- 4 August 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 3(83),p. 51-59
Effect of obesity and blood pressure dipping status on left ventricular mass in normotensive young adults
Despite the established links between obesity, blood pressure variability, and cardiovascular risks, the specific impact of the interaction between obesity and non-dipping blood pressure status on left ventricular mass (LVM) in normotensive individuals remains underexplored. Most studies have focused on hypertensive populations, leaving a critical gap in understanding how these factors contribute to cardiovascular changes in normotensive young adults. This study aims to address this gap by examining the combined effects of obesity and blood pressure dipping status on LVM in a normotensive cohort of young subjects. Methods: This cross-sectional study was conducted at Hasanuddin University Hospital and Central General Hospital (RSUP) Dr. Wahidin Sudirohusodo from March 2023, with a sample of 63 subjects divided into 32 dippers and 31 non-dippers. Interviews and ambulatory blood pressure monitoring (ABPM) were used to collect blood pressure data and history of hypertension. LVM measurements were obtained via echocardiography. Data were analyzed using SPSS version 25, with statistical significance set at p<0.05. Results: LVM was significantly greater in males, obese individuals, and non-dippers compared to females, non-obese individuals, and dippers (178.2±141.6 g vs. 102.68±32.1 g; 156.3±124.3 g vs. 101.39±26.02 g; 150.5±118.6 g vs. 103.5±38.4 g with p=0.029, p=0.026, p=0.037, respectively). Both non-dipping status and obesity significantly affected LVM, with odds ratios of 4.27 and 3.31, respectively (p<0.05). Non-dipping status was the dominant factor affecting LVM, with the lowest risk observed in the dipping and non-obese group (OR=1.00). Conclusion: Obesity and non-dipping blood pressure status, and their interaction, increase LVM. It is necessary to control obesity in young adults even if they are normotensive.
- 4 August 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 3(83),p. 51-59
Open AccessEffect of obesity and blood pressure dipping status on left ventricular mass in normotensive young adults
Despite the established links between obesity, blood pressure variability, and cardiovascular risks, the specific impact of the interaction between obesity and non-dipping blood pressure status on left ventricular mass (LVM) in normotensive individuals remains underexplored. Most studies have focused on hypertensive populations, leaving a critical gap in understanding how these factors contribute to cardiovascular changes in normotensive young adults. This study aims to address this gap by examining the combined effects of obesity and blood pressure dipping status on LVM in a normotensive cohort of young subjects. Methods: This cross-sectional study was conducted at Hasanuddin University Hospital and Central General Hospital (RSUP) Dr. Wahidin Sudirohusodo from March 2023, with a sample of 63 subjects divided into 32 dippers and 31 non-dippers. Interviews and ambulatory blood pressure monitoring (ABPM) were used to collect blood pressure data and history of hypertension. LVM measurements were obtained via echocardiography. Data were analyzed using SPSS version 25, with statistical significance set at p<0.05. Results: LVM was significantly greater in males, obese individuals, and non-dippers compared to females, non-obese individuals, and dippers (178.2±141.6 g vs. 102.68±32.1 g; 156.3±124.3 g vs. 101.39±26.02 g; 150.5±118.6 g vs. 103.5±38.4 g with p=0.029, p=0.026, p=0.037, respectively). Both non-dipping status and obesity significantly affected LVM, with odds ratios of 4.27 and 3.31, respectively (p<0.05). Non-dipping status was the dominant factor affecting LVM, with the lowest risk observed in the dipping and non-obese group (OR=1.00). Conclusion: Obesity and non-dipping blood pressure status, and their interaction, increase LVM. It is necessary to control obesity in young adults even if they are normotensive.
- Open Access
- 4 December 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 13 (1)
The correlation between serum fibroblast growth factor-23 levels and left ventricular hypertrophy in chronic kidney disease patients
Introduction: Hyperphosphatemia in chronic kidney disease (CKD) patients can stimulate the production of the fibroblast growth factor-23 (FGF-23) phosphatonin hormone, which is associated with cardiac remodeling resulting in left ventricular hypertrophy (LVH). Objectives: To determine the correlation between FGF-23 level and LVH incidence in CKD patients and establish the associated risk factors. Materials and Methods: This cross-sectional study involved 74 CKD patients who were classified as stage 3 (n=18), stage 4 (n=17), stage 3 (n=18), dialysis stage 5 (n=20), or non-dialysis stage 5 (n=19). The FGF-23 levels of the patients were measured using the ELISA (enzyme-linked immunosorbent assay) kit method, whereas a cardiologist verified LVH using an echocardiographic examination based on the LVH criteria of >95 g/m2 for females and >115 g/m2 for males. Results: A significant difference was observed in the mean FGF-23 values between the LVH and non-LVH patients (443.27±437.047 RU/mL and 172.68±185.56 RU/mL, respectively; P123.95 RU/mL had a 3.6 times greater risk of LVH compared to those with values ≤123.95 RU/mL. The LVH risk factors of gender and age, as well as hypertension, diabetes mellitus, and obesity diagnoses were not associated with LVH incidence in CKD patients. Conclusion: A significant association was found between FGF-23 level and LVH incidence in CKD patients, in which an FGF-23 level >123.95 RU/mL corresponded to a 3.6 times greater risk of LVH than those with FGF-23 levels below this value.
- 4 December 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 13 (1)
Open AccessThe correlation between serum fibroblast growth factor-23 levels and left ventricular hypertrophy in chronic kidney disease patients
Introduction: Hyperphosphatemia in chronic kidney disease (CKD) patients can stimulate the production of the fibroblast growth factor-23 (FGF-23) phosphatonin hormone, which is associated with cardiac remodeling resulting in left ventricular hypertrophy (LVH). Objectives: To determine the correlation between FGF-23 level and LVH incidence in CKD patients and establish the associated risk factors. Materials and Methods: This cross-sectional study involved 74 CKD patients who were classified as stage 3 (n=18), stage 4 (n=17), stage 3 (n=18), dialysis stage 5 (n=20), or non-dialysis stage 5 (n=19). The FGF-23 levels of the patients were measured using the ELISA (enzyme-linked immunosorbent assay) kit method, whereas a cardiologist verified LVH using an echocardiographic examination based on the LVH criteria of >95 g/m2 for females and >115 g/m2 for males. Results: A significant difference was observed in the mean FGF-23 values between the LVH and non-LVH patients (443.27±437.047 RU/mL and 172.68±185.56 RU/mL, respectively; P123.95 RU/mL had a 3.6 times greater risk of LVH compared to those with values ≤123.95 RU/mL. The LVH risk factors of gender and age, as well as hypertension, diabetes mellitus, and obesity diagnoses were not associated with LVH incidence in CKD patients. Conclusion: A significant association was found between FGF-23 level and LVH incidence in CKD patients, in which an FGF-23 level >123.95 RU/mL corresponded to a 3.6 times greater risk of LVH than those with FGF-23 levels below this value.